Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice.
The data below is based on a total of 3,906 patients in clinical studies who received methylphenidate hydrochloride extended-release tablets. Patients aged 6 up to 65 years old with ADHD were evaluated in 6 controlled clinical studies and 11 open-label clinical studies
[see Table 3].
Table 3: Methylphenidate Hydrochloride Extended-Release Tablets-treated Patients in Double-Blind and Open-Label Clinical Studies
| Patient Population | N | Dosage Range |
| Pediatric patients 6 to 12 years of age | 2,216 | 18 to 54 mg once daily |
| Adolescents | 502 | 18 to 72 mg once daily |
| Adults up to 65 years of age | 1,188 | 18 to 108 mg once daily |
The most common adverse reactions (≥5%) in double-blind clinical trials were:
- Pediatric patients: upper abdominal pain
[see Table 4].
- Adults: decreased appetite, headache, dry mouth, nausea, insomnia, anxiety, dizziness, weight decreased, irritability, tachycardia, and hyperhidrosis
[see Table 5].
The most common adverse reactions associated with methylphenidate hydrochloride extended-release tablets discontinuation (≥1%) from the pediatric and adult clinical trials were anxiety, irritability, insomnia, and increased blood pressure.
Most Common Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials: Adverse reactions in either the pediatric or adult double-blind adverse reactions tables may be relevant for both patient populations.
Adverse Reactions in Pediatric Patients Aged 6 years and Older
Table 4 displays adverse reactions reported in 2% or more of methylphenidate hydrochloride extended-release tablets -treated pediatric patients ages 6 and older with ADHD in 4 placebo-controlled, double-blind clinical trials.
Table 4: Most Common Adverse Reactions
1in Pediatric Patients 6 Years of Age and Older with ADHD in 4 Placebo-Controlled, Double-Blind Clinical Trials
| Methylphenidate
Hydrochloride Extended-Release Tablets (n=321)
| Placebo
(n=318)
|
| Upper abdominal pain | 6% | 4% |
| Insomnia
2 | 3% | 1% |
| Nasopharyngitis | 3% | 2% |
| Vomiting | 3% | 2% |
| Pyrexia | 2% | 1% |
1Reported in ≥ 2% of methylphenidate hydrochloride extended-release tablets-treated patients
2Initial insomnia (methylphenidate hydrochloride extended-release tablets =0.6%) and insomnia (methylphenidate hydrochloride extended-release tablets =2.2%) terms were combined into Insomnia.
Adverse Reactions in Adults
Table 5 lists the adverse reactions reported in 2% or more of methylphenidate hydrochloride extended-release tablets-treated adults with ADHD in 2 placebo-controlled, double-blind clinical trials.
Table 5: Most Common Adverse Reactions1 in Adults with ADHD in 2 Placebo-Controlled, Double-Blind Clinical Trials
1Reported in ≥ 2% of methylphenidate hydrochloride extended-release tablets -treated patients
2Included dosages up to 108 mg/day (1.5 times the maximum recommended dosage).
Other Adverse Reactions Observed in Clinical Trials of Methylphenidate Hydrochloride Extended-Release Tablets
The following adverse reactions occurred in less than 2% of methylphenidate hydrochloride-treated patients ages 6 to 65 years of age in the double-blind and open-label clinical ADHD trials.
•
Blood and Lymphatic System Disorders: Leukopenia
•
Cardiac Disorders: Cardiac murmur, Hypertension, Heart rate increased
•
Ear and Labyrinth Disorders: Vertigo
•
Eye Disorders: Accommodation disorder, Dry eye, Vision blurred
•
Gastrointestinal Disorders: Abdominal discomfort/pain, Constipation, Diarrhea, Vomiting
•
General Disorders and Administration Site Conditions: Asthenia, Fatigue, Feeling jittery, Thirst
•
Hepatobiliary Disorders: Hepatic enzymes increased
•
Infections and Infestations: Sinusitis
•
Metabolism and Nutrition Disorders: Anorexia
•
Musculoskeletal and Connective Tissue Disorders: Muscle spasms, Muscle tightness
•
Nervous System Disorders: Lethargy, Paresthesia, Psychomotor hyperactivity, Sedation, Somnolence, Tension headache
•
Psychiatric Disorders: Affect lability, Aggression, Anger, Bruxism, Confusional state, Depression, Hypervigilance, decreased libido, Mood swings, Panic attack, Sleep disorder, Tearfulness, Tension, Tic
•
Reproductive System and Breast Disorders: Erectile dysfunction
•
Respiratory, Thoracic and Mediastinal Disorders: Cough, Dyspnea, Oropharyngeal pain
•
Skin and Subcutaneous Tissue Disorders: Rash
•
Vascular Disorders:Hot flush
Discontinuation Due to Adverse Reactions
In the 2 placebo-controlled studies in adults with ADHD, 25 (6%) methylphenidate hydrochloride extended-release tablets -treated patients and 6 (3%) placebo-treated patients discontinued due to an adverse reaction. In the methylphenidate hydrochloride extended-release tablets group, adverse reactions leading to discontinuation with an incidence of >0.5% were anxiety (1.7%), irritability (1.4%), increased blood pressure (1%), and nervousness (0.7%). In the placebo group, adverse reactions leading to discontinuation with an incidence of >0.5% were increased blood pressure (0.9%) and depressed mood (0.9%).
In the 11 open-label studies in patients 6 to 65 years of age with ADHD, 266 (7%) methylphenidate hydrochloride extended-release tablets-treated patients discontinued due to an adverse reaction including insomnia (1.2%), irritability (0.8%), anxiety (0.7%), decreased appetite (0.7%), and tic (0.6%).
Blood Pressure and Heart Rate Increases
• In the 1-week treatment, controlled trials in pediatric patients 6 to 12 years of age with ADHD (Studies 1 and 2) [see Clinical Studies (14.2)], both the methylphenidate hydrochloride extended-release tablets once daily group and the methylphenidate three times daily group increased resting pulse by an average of 2 to 6 beats per minute (bpm) and increased the average systolic and diastolic blood pressure roughly 1 to 4 mm Hg during the day, relative to placebo.
• In the randomized withdrawal portion of the double-blind, placebo-controlled trial with pediatric patients 13 to 17 years of age with ADHD (Study 4) [see Clinical Studies (14.3)], mean increases from baseline in resting pulse rate were observed with methylphenidate hydrochloride extended-release tablets and placebo at the end of the double-blind phase (5 and 3 beats/minute (bpm), respectively). At the end of four weeks of treatment, mean increases from baseline in blood pressure for methylphenidate hydrochloride extended-release tablets and placebo-treated patients were 0.7 and 0.7 mm Hg (systolic) and 2.6 and 1.4 mm Hg (diastolic), respectively.
• In the 7-week dose-titration, placebo-controlled study in adults 18 to 65 years of age with ADHD (Study 5) [see Clinical Studies (14.4)], mean changes from baseline in resting pulse rate were 3.6 in methylphenidate hydrochloride extended-release tablets -treated patients and -1.6 for placebo-treated patients after 7 weeks of treatment. Mean changes from baseline in blood pressure after 7 weeks of treatment in methylphenidate hydrochloride extended-release tablets-treated and placebo-treated patients were –1.2 and –0.5 mm Hg (systolic) and 1.1 and 0.4 mm Hg (diastolic), respectively [see Warnings and Precautions (5.3)].
• In the 5-week fixed-dose, placebo-controlled trial in adults 18 to 65 years of age with ADHD (Study 5) [see Clinical Studies (14.4)], dose-dependent mean increases of 3.9 to 9.8 bpm from baseline in standing pulse rate were observed with methylphenidate hydrochloride extended-release tablets -treated patients and 2.7 bpm with placebo-treated patients at the end of 5 weeks. Mean changes from baseline in standing blood pressure after 5 weeks of treatment ranged from 0.1 to 2.2 mm Hg (systolic) and -0.7 to 2.2 mm Hg (diastolic) for methylphenidate hydrochloride extended-release tablets-treated patients and 1.1 mm Hg (systolic) and 1.8 mm Hg (diastolic) for placebo-treated patients.